Related Experiment Video
Updated: Jul 10, 2026
10:00
High-throughput Quantitative Real-time RT-PCR Assay for Determining Expression Profiles of Types I and III Interferon Subtypes
Published on: March 24, 2015
Appropriate use of interferon beta-1a in multiple sclerosis
1State University of New York at Buffalo, Department of Neurology, Buffalo General Hospital, Buffalo, New York 14203, USA. ner005@pol.bgh.edu
Summary
Interferon beta-1a is a new treatment for relapsing multiple sclerosis (MS) that delays disability progression and reduces relapses and brain lesions. This therapy may alter the fundamental course of MS, offering new hope for patients.
Area of Science:
- Neurology
- Immunology
Background:
- Multiple sclerosis (MS) is a chronic, inflammatory, demyelinating disease of the central nervous system, commonly affecting young adults.
- Traditional treatments like ACTH and methylprednisolone improve relapses but not disability or the chronic disease course.
- Interferon beta represents a significant advancement in MS treatment.
Purpose of the Study:
- To evaluate the efficacy of recombinant interferon beta therapies in treating relapsing multiple sclerosis.
- To determine if interferon beta treatments can impact physical disability progression and other disease aspects.
Main Methods:
- Review of clinical trials involving interferon beta-1b and interferon beta-1a for relapsing MS.
- Analysis of data on clinical relapses, physical disability progression, and MRI-detected brain lesions.
Main Results:
- Interferon beta-1b showed efficacy but no effect on physical disability progression.
- Intramuscular and subcutaneous interferon beta-1a significantly delayed sustained physical disability progression.
- Interferon beta-1a also reduced clinical relapses and acute/chronic brain lesions on MRI.
Conclusions:
- Interferon beta-1a is the first MS treatment to demonstrate a prophylactic effect on physical disability progression.
- Interferon beta-1a treatment is believed to alter the fundamental course of relapsing MS.
- The exact mechanisms of interferon beta's therapeutic benefits are still under investigation.
Related Concept Videos
01:30Inhibitors of Viral Protein Synthesis
Protein synthesis is indispensable for viral replication, as viruses lack the cellular machinery required for this process and must hijack the host's translational apparatus. In response, host cells deploy a critical innate immune defense involving interferons, specialized cytokines that play a central role in inhibiting viral propagation.Upon viral detection, infected cells release interferons that bind to receptors on adjacent uninfected cells, activating the JAK-STAT signaling pathway and...
01:19Multiple Sclerosis l: Introduction
Multiple sclerosis is a chronic autoimmune disease of the central nervous system (CNS) that affects the brain, spinal cord, and optic nerves. It is an inflammatory demyelinating disorder and a leading cause of neurological disability in young adults.EpidemiologyMS commonly begins between 20 and 40 years of age and is twice as common in women. Its exact cause remains unclear, but genetic susceptibility contributes, with higher risk in first-degree relatives and identical twins. A greater...
01:29Drugs for Treatment of Crohn's Disease in IBD Using Immunomodulatory Agents
Crohn's disease is an inflammatory bowel disorder marked by chronic inflammation of the GI tract. Various treatment strategies for Crohn's disease are employed, such as immunomodulatory agents, glucocorticoids, and biologics or anti-TNF therapy. Azathioprine (Imuran), a commonly used immunomodulatory drug for Crohn's disease, is converted in the body to mercaptopurine, which inhibits purine biosynthesis and cell proliferation. Both are utilized in severe cases of Inflammatory Bowel Disease...
01:24Drugs for Treatment of Crohn's Disease in IBD Using Biologic Agents: Anti-TNF
Tumor Necrosis Factor (TNF), a proinflammatory cytokine, contributes significantly to the inflammation seen in Crohn's disease. It exists as soluble TNF and membrane-bound TNF, with actions mediated through TNF receptors (TNFR). TNFR activation leads to the release of proinflammatory cytokines, T-cell activation, collagen production, and leukocyte migration, all contributing to inflammation in Crohn's disease. Anti-TNF monoclonal antibodies, namely infliximab (Remicade), adalimumab (Humira),...